https://wilhelmvanzyl.com/ A working journal of ideas, people, capital and opportunity across Africa. https://wilhelmvanzyl.com/notebook/why-african-rare-disease-is-a-market/Unmet need is not charity; the quiet build-out of access pathways across Africa describes a commercial opportunity wearing a moral disguise. https://wilhelmvanzyl.com/notebook/quiet-repricing-of-frontier-credit/Default makes headlines; mispricing makes returns. Which African issuers were punished for their neighbours' problems rather than their own? https://wilhelmvanzyl.com/conversations/economics-of-decentralised-trials/A clinical-operations lead, running multi-country studies, on what actually makes a trial cheaper, and what only looks like it does. https://wilhelmvanzyl.com/notebook/section-21-and-the-architecture-of-access/South Africa's named-patient route looks like a loophole; read closely it is a working blueprint for how unregistered medicines reach patients. https://wilhelmvanzyl.com/conversations/what-regulators-actually-want/A former medicines-agency reviewer on timelines, evidence, and the gap between what sponsors submit and what regulators need. https://wilhelmvanzyl.com/notebook/notes-on-building-a-laboratory-company/Field notes from inside Veltrion Laboratories on why regulated, unglamorous, infrastructure-heavy businesses are the most defensible bets in African healthcare. https://wilhelmvanzyl.com/notebook/real-cost-of-sahpra-delays/Registration backlogs are usually counted in months. The more useful number is what those months actually cost a sponsor, and who pays it. https://wilhelmvanzyl.com/notebook/africa-is-not-one-market/The single most expensive assumption foreign operators make about the continent, and what changes once you stop making it.